[Skip to Navigation]
Comment & Response
January 8, 2020

Using Perivascular Fat Attenuation Index to Monitor Coronary Inflammation in Patients With Psoriasis—Reply

Author Affiliations
  • 1National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
  • 2New York University School of Medicine, New York
  • 3Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
JAMA Cardiol. 2020;5(3):359-360. doi:10.1001/jamacardio.2019.5333

In Reply We appreciate the correspondence brought forward by Sutanto et al, who support our work1 and facilitate further fruitful discussion of the study. To address the first point regarding markers of inflammation in psoriasis, although C-reactive protein (CRP) is less specific, we used a high-sensitivity assay. High-sensitivity CRP is an independent predictor of future myocardial infarction and stroke beyond cholesterol.2 Moreover, although interleukin 18, tumor necrosis factor α, and pentraxin have been implicated in coronary artery disease, they do not add prognostic value over high-sensitivity CRP. Finally, aortic 18F-fluorodeoxyglucose positron emission tomography (PET) uptake, a robust marker of inflammation, has been used to demonstrate favorable association of biologic therapy with aortic 18F-fluorodeoxyglucose uptake.3

Add or change institution